Overview

Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Advanced Malignancies and Hepatic Impairment

Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the safety and efficacy of carfilzomib, including measuring the amount of the study drug in the blood at certain times following dosing. This study is being done in people with varying degrees of liver function to see if they respond differently to the study drug.
Phase:
Phase 1
Details
Lead Sponsor:
Amgen
Onyx Therapeutics, Inc.